Inoviq Ltd has released a press release.
SubB2M/CA15.3 Clinical Validation Data Investor Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from Inoviq
- Excellent Clinical Data for SubB2M/CA15-3 Breast Cancer Test
- ISEV Meeting Presentations
- Appendix 4C and Quarterly Activities Report - March 2023
- Appendix 4D and Half Year Financial Report
- Positive results for SubB2M Breast Cancer Test
Later from Inoviq
- INOVIQ and Promega announce Global Joint Marketing Agreement
- Appendix 4C and Quarterly Activities Report - June 2023
- INOVIQ Investor Briefing
- Exo-oc program completes serum equivalence study
- IIQ and ResearchDx sign USA EXO-NET Services Agreement
Follow Inoviq into a list and get an email when it puts out news.
Follow Inoviq